Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021
Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021 March 15, 2021 08:00 ET | Source: Ovid Therapeutics Inc. Ovid Therapeutics Inc. New York, New York, UNITED STATES Announced signing of transaction transferring Ovid’s 50% of global rights to develop and commercialize soticlestat (TAK-935/OV935) to Takeda, under which Ovid is eligible to receive up to $856 million in payments, including an upfront payment of $196 million at closing Two pivotal Phase 3 trials of soticlestat in Dravet syn...
Source: globenewswire.com